Another Win for Mesothelioma Immunotherapy Drug Keytruda

There has been another win for one of the most promising new drugs for mesothelioma, the immunotherapy drug Keytruda (pembrolizumab). The makers of Keytruda today announced  that, when combined with the mesothelioma drug Alimta (pemetrexed) and the platinum-based drug cisplatin, it significantly extended the survival of lung cancer patients. According to Bloomberg, the news will likely make Keytruda an even more popular choice among immunotherapy … Continue reading Another Win for Mesothelioma Immunotherapy Drug Keytruda »

Predicting Mesothelioma Survival: A New Model

mesothelioma diagnosis

Could a geometric diagram hold the key to predicting the treatment outcomes of patients with malignant pleural mesothelioma? A team of thoracic surgery experts at China’s Fudan University believe the answer is yes. The team has developed such a diagram, called a nomogram, and used it to demonstrate the connection between a list of prognostic factors and actual mesothelioma survival. Predicting Mesothelioma Prognosis The new … Continue reading Predicting Mesothelioma Survival: A New Model »

Modified Surgical Approach May Boost Pleural Mesothelioma Survival

For people with malignant pleural mesothelioma, surgery often offers the best odds of survival. But surgery can also come at a heavy cost in terms of pain, post-surgical side effects, and quality of life. Even lung-sparing pleurectomy with decortication, the least radical of the two major types of mesothelioma surgery, can cause life-threatening complications. But a new Italian study suggests that it may be possible … Continue reading Modified Surgical Approach May Boost Pleural Mesothelioma Survival »

Many Pleural Mesothelioma Patients May Be Missing Out on Life-Extending Treatments

Support for mesothelioma patients

Too many patients with malignant pleural mesothelioma are not getting the trimodality treatment protocol that could significantly change their outcomes. That is the finding of a newly-published study conducted at MD Anderson Cancer Center in Houston, Texas. Researchers reviewed the records of more than 20,000 patients in the National Cancer Database with a definitive diagnosis of pleural mesothelioma between 2004 and 2014. They discovered that, … Continue reading Many Pleural Mesothelioma Patients May Be Missing Out on Life-Extending Treatments »

Blocking This Cellular Process Could Help Mesothelioma Chemotherapy Work Better

Researchers in California and Boston say blocking a process by which cells break down and recycle their components into new cells could make mesothelioma tumors more susceptible to chemotherapy. Although the process, known as autophagy, is a natural part of the lives of cells, it can also be induced by certain drugs. Emerging research suggests that the multi-stage process is not only more complex than … Continue reading Blocking This Cellular Process Could Help Mesothelioma Chemotherapy Work Better »

Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France

France has a new standard of care for people with unresectable malignant pleural mesothelioma. Along with the chemotherapy drugs cisplatin and pemetrexed (Alimta), French doctors are now regularly also using bevacizumab (Avastin) to boost the effectiveness of mesothelioma chemotherapy. The addition of Avastin to standard mesothelioma care came after the 2016 French-led mesothelioma avastin cisplatin pemetrexed study (MAPS) showed that the VEGF inhibitor improved mesothelioma … Continue reading Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France »

New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients

A new way of delivering chemotherapy drugs to the site of a peritoneal mesothelioma tumor has some unique benefits, but can also be risky. The technique, called pressurized intraperitoneal aerosol chemotherapy (PIPAC) allows doctors to “spray” a solution of chemotherapy drugs directly onto peritoneal tumors through small ports in the abdomen. The intention is to uniformly coat the tumor and help keep chemotherapy drugs in … Continue reading New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients »

New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy

Researchers in the Netherlands have unveiled what may be a major breakthrough in the chemotherapeutic treatment of malignant mesothelioma. Malignant mesothelioma, a rare and virulent cancer caused by asbestos exposure, is notoriously resistant to standard cancer treatments, including chemotherapy. Even the only chemotherapy drug specifically approved for the treatment of mesothelioma, Alimta (pemetrexed), only works for some patients. Now, a new study published in the … Continue reading New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy »

New Chemotherapy Booster May Extend Mesothelioma Survival

Cancer researchers say the VEGF-inhibitor nintedanib (Ofev) extended mesothelioma survival by more than five months in patients on standard chemotherapy in a new trial. That is among the findings of a recently-published Phase II study of nintedanib as an adjunct therapy to pemetrexed (Alimta) and cisplatin for malignant pleural mesothelioma. Nintedanib Trial Details Nintedanib is currently used to treat idiopathic pulmonary fibrosis and some types … Continue reading New Chemotherapy Booster May Extend Mesothelioma Survival »

New Report Reveals Disparities in Mesothelioma Treatment

A new study of mesothelioma treatment and survival in the US contains some disturbing facts about treatment trends. Among them is the fact that people over 70 are much less likely to get any treatment for malignant mesothelioma, a rare but but fast-growing malignancy that can be quickly fatal. In fact, nearly a third of mesothelioma patients receive no therapy at all. The study was … Continue reading New Report Reveals Disparities in Mesothelioma Treatment »

Get your free copy of
“Surviving Mesothelioma” Today!